Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25268993 | 0.83 | BCL2L1 (0.59) | CA1CA2ALDH1A1MAOAKMT2A | |
| SCHEMBL2290762 | 0.79 | PTGS2 (0.48) | MMP2CA1CA2MMP1MMP9 | |
| SCHEMBL8577885 | 0.79 | SOS1 (0.52) | MMP2CA1CA2MMP1MMP9 | |
| SCHEMBL2170132 | 0.78 | CA1 (0.50) | MMP2CA1CA2MMP1MMP9 | |
| SCHEMBL25256280 | 0.78 | MEN1 (0.57) | CA1CA2MAOAMEN1KMT2A | |
| SCHEMBL548298 | 0.77 | MMP2 (0.54) | MMP2CA1CA2MMP1MMP9 | |
| SCHEMBL2121770 | 0.77 | HSD11B1 (0.55) | MMP2CA1CA2MMP1MMP9 | |
| SCHEMBL79787 | 0.77 | HSD11B1 (0.55) | MMP2CA1CA2MMP1MMP9 | |
| SCHEMBL30072318 | 0.77 | HSD11B1 (0.55) | MMP2CA1CA2MMP1MMP9 | |
| SCHEMBL4328574 | 0.77 | HSD11B1 (0.55) | MMP2CA1CA2MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060078494-A1 | Use of inhibitors of 24-hydroxylase in the treatment of cancer | SAPPHIRE THERAPEUTICS, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20060074109-A1 | Use of inhibitors of 24-hydroxylase in the treatment of cancer | SAPPHIRE THERAPEUTICS, INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2006036892-A2 | USE OF INHIBITORS OF 24-HYDROXYLASE IN THE TREATMENT OF CANCER | SAPPHIRE THERAPEUTICS, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006037023-A2 | USE OF INHIBITORS OF 24-HYDROXYLASE IN THE TREATMENT OF CANCER | SAPPHIRE THERAPEUTICS, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074109-A1 | Use of inhibitors of 24-hydroxylase in the treatment of cancer | CYP2R1, CYP24A1, CYP27B1 | MMP2 250/4885CA1 363/4885CA2 439/4885 |
| US-20060078494-A1 | Use of inhibitors of 24-hydroxylase in the treatment of cancer | CYP46A1, EI24, CYP17A1 | MMP2 149/4885CA1 2365/4885CA2 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.